Ipilimumab for Patients with Relapse after Allogeneic Transplantation
2016 · New England Journal of Medicine · 588 citations
https://doi.org/10.1056/nejmoa1601202
C
Caitlin Costello
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
151
Papers
4.9K
Citations
31
h-index
57
i10-index
Caitlin Costello is an academic researcher from University of San Diego. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & CAR-T cell therapy research. The author has an h-index of 31, co-authored 129 publications.
ORCID: 0000-0002-3405-5937Papers by this author
worksElranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
2023 · Nature Medicine · 126 citations
https://doi.org/10.1038/s41591-023-02589-w
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
2021 · Blood Cancer Journal · 107 citations
https://doi.org/10.1038/s41408-021-00432-4
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
2024 · Blood · 43 citations
https://doi.org/10.1182/blood.2024025746
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
2024 · Blood Cancer Journal · 29 citations
https://doi.org/10.1038/s41408-024-01088-6
Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells
2021 · STAR Protocols · 7 citations
https://doi.org/10.1016/j.xpro.2021.100565
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat